Back to Search
Start Over
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
- Source :
- Nicolini , F E , Mauro , M J , Martinelli , G , Kim , D-W , Soverini , S , Müller , M C , Hochhaus , A , Cortes , J , Chuah , C , Dufva , I H , Apperley , J F , Yagasaki , F , Pearson , J D , Peter , S , Sanz Rodriguez , C , Preudhomme , C , Giles , F , Goldman , J M & Zhou , W 2009 , ' Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation ' , Blood , vol. 114 , no. 26 , pp. 5271-8 .
- Publication Year :
- 2009
-
Abstract
- Udgivelsesdato: 2009-Dec<br />The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-alpha in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.
Details
- Database :
- OAIster
- Journal :
- Nicolini , F E , Mauro , M J , Martinelli , G , Kim , D-W , Soverini , S , Müller , M C , Hochhaus , A , Cortes , J , Chuah , C , Dufva , I H , Apperley , J F , Yagasaki , F , Pearson , J D , Peter , S , Sanz Rodriguez , C , Preudhomme , C , Giles , F , Goldman , J M & Zhou , W 2009 , ' Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation ' , Blood , vol. 114 , no. 26 , pp. 5271-8 .
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1322593807
- Document Type :
- Electronic Resource